查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2011699

慢性阻塞性肺病（COPD）治疗市场：依产品类型、药物类别、给药途径及通路划分－2026-2032年全球市场预测

Chronic Obstructive Pulmonary Disease Treatment Market by Product Type, Drug Class, Route Of Administration, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，慢性阻塞性肺病(COPD) 治疗市场价值将达到 899.5 亿美元，到 2026 年将增长至 966.4 亿美元，到 2032 年将达到 1535 亿美元，复合年增长率为 7.93%。

主要市场统计数据
基准年 2025 899.5亿美元
预计年份：2026年 966.4亿美元
预测年份 2032 1535亿美元
复合年增长率 (%) 7.93%

重点突出、结合实际情况的介绍，概述了正在重塑全球 COPD 治疗路径的临床进展、医疗设备创新和商业性因素。

慢性阻塞性肺病（COPD）仍然是发病率和医疗资源消耗的主要原因之一，临床、商业和政策领域的相关人员必须适应治疗方法和给药方法创新步伐的加快。长效支气管扩张剂、标靶抗发炎策略和吸入装置设计的进步正在改变人们对症状控制和急性恶化预防的预期。同时，报销模式的转变以及对病人依从性和品质指标的日益重视，正在重新定义支付方和医疗服务提供者眼中的价值。

对临床、技术和政策领域正在发生的整合变化进行了清晰的概述，这些变化正在重新定义 COPD 管理的治疗策略和商业模式。

慢性阻塞性肺病（COPD）的治疗现况正经历着变革，这主要得益于临床实务、技术和政策的进步。临床上，治疗模式正从单一疗法转向联合治疗，即结合长效支气管扩张剂和抗发炎药物，以应对患者的不同表型。随着临床治疗的不断发展，标靶药物和支持疗法也在日趋成熟，旨在有效控制症状并降低急性恶化风险。

对不断变化的进口关税措施如何重塑整个 COPD 治疗市场的供应链、筹资策略和临床可用性进行全面分析。

影响药品原料、成品吸入器和契约製造原料的关税措施的推出和加强，为供应链负责人和销售团队带来了重大考量。关税相关的成本压力往往表现为原材料和零件价格上涨、物流和海关手续日益复杂，以及与供应商关係的重组。实际上，製造商正在加快采取措施，透过探索替代采购管道、与供应商谈判签订长期价格合约以及扩大国内或本地产能来降低关税波动带来的风险。

从综合细分观点，重点阐述产品类型、药物类别、给药途径和分销管道如何相互作用，从而决定 COPD 治疗中的临床应用和商业策略。

基于细分市场的洞察揭示了治疗需求、临床应用和商业管道如何在产品类型、药物类别、给药途径和通路之间相互作用。就产品类型而言，抗生素、皮质类固醇、长效支气管扩张剂、磷酸二酯酶-4抑制剂和短效支气管扩张剂之间的差异分别代表着不同的临床作用：抗生素通常间歇性用于感染疾病控制；皮质类固醇以各种剂型发挥抗发炎作用；长效支气管扩张剂作为维持治疗症状；这些功能差异会影响处方集纳入、病患教育重点和生产週期。

一份详细的区域评估报告，阐述了医疗保健系统、法律规范和供应链能力如何影响世界各地的 COPD 治疗方法。

区域趋势对治疗重点、监管路径和供应链决策产生了意义深远且独特的影响。在美洲，医疗保健系统通常优先考虑基于价值的支付模式和能够支持全面护理和药物依从性计划的大规模综合医疗保健网络。在此背景下，製药公司需要证明其产品在真实临床环境中的有效性，并与医疗保健系统合作开展试点项目，整合数位化药物依从性工具和病患教育，以减少病情加重和再入院。

决定 COPD 治疗领域企业绩效和合作的策略考量因素，包括竞争定位、伙伴关係模式和创新重点。

慢性阻塞性肺病（COPD）领域的企业竞争格局主要受治疗方法差异化、医疗设备创新、策略伙伴关係和业务永续营运等因素驱动。创新生物製药公司持续专注于差异化联合治疗和标靶抗发炎策略，以期在不同表型亚群中展现临床疗效。医疗设备製造商则致力于研发符合人体工学且具备数位化连接功能的产品，以减少误用并收集用药依从性数据，从而提升其对支付方和医疗服务提供者的价值提案。

为专注于产品差异化、供应链韧性、数位整合和支付方合作的高阶主管提供实用建议，以在 COPD 治疗领域建立可持续的竞争优势。

产业领导企业可以透过整合符合支付方期望和患者需求的营运和临床优先事项来提升自身竞争力。首先，将医疗设备设计改进与实证医学方案结合，可确保新剂型得到结果数据的支持，从而证明其能够减少误用并提高患者依从性。将产品创新与强大的上市后监测和真实世界数据 (RWE) 的产生相结合，可提供检验价值提案、支持扩大适应症和医疗保险报销谈判所需的资讯。

透过文献整合、专家访谈、实际应用分析和供应链映射等严谨且多方面的研究途径，获得了切实可行的见解。

本分析所依据的研究采用了一种多方面方法，旨在整合临床、商业和供应链讯号。透过对同侪审查文献和监管指导文件的系统性回顾，我们确立了临床背景，并为治疗方法和医疗设备的检验提供了基础。此外，我们也对临床专业人员、医院药剂师、医疗设备工程师和供应链管理人员进行了定性访谈，以了解他们对用药依从性挑战、医疗设备易用性和采购压力等方面的实际观点。

一项权威的综合分析强调了整合临床创新、医疗设备的易用性和供应链韧性对于加快 COPD 患者的治疗效果和商业性成功至关重要。

总之，慢性阻塞性肺病（COPD）治疗生态系统正处于一个转折点，临床创新、医疗设备进步、供应链策略和支付方期望在此交汇融合，重新定义了价值主张。整合实证治疗方法方案、提升医疗设备易用性以及提供数位化用药依从性支持的相关人员，能够更好地实现病患疗效。同时，商业性韧性——包括采购多元化、确保区域製造地以及协同需求预测——对于商业成功至关重要，能够保障供应稳定，并降低可能导致成本增加或供应中断的关税和物流风险。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：慢性阻塞性肺病（COPD）治疗市场：依产品类型划分

  • 抗生素
  • 皮质类固醇
  • 长效支气管扩张剂
  • 磷酸二酯酶-4抑制剂
  • 短效支气管扩张剂

第九章：慢性阻塞性肺病（COPD）治疗市场：依药物类别划分

  • 抗胆碱能药物
  • β-激动剂
  • 皮质类固醇
  • 甲基黄嘌呤类类药物

第十章：慢性阻塞性肺病（COPD）治疗市场：依给药途径划分

  • 吸入
    • 干粉吸入器
    • 定量喷雾吸入器
    • 喷雾器
  • 静脉注射
  • 口服

第十一章：慢性阻塞性肺病（COPD）治疗市集：依分销管道划分

  • 医院药房
  • 网路药房
  • 零售药房

第十二章：慢性阻塞性肺病（COPD）治疗市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：慢性阻塞性肺病（COPD）治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章慢性阻塞性肺病（COPD）治疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 美国慢性阻塞性肺病（COPD）治疗市场

第十六章 中国慢性阻塞性肺病（COPD）治疗市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AstraZeneca PLC
  • Aurobindo Pharma Ltd.
  • Boehringer Ingelheim International GmbH
  • Chiesi Farmaceutici SpA
  • Cipla Ltd.
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals Ltd.
  • Hikma Pharmaceuticals PLC
  • Lupin Limited
  • Merck & Co., Inc.
  • Mylan NV
  • Novartis AG
  • Orion Corporation
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-43676CF42C41

The Chronic Obstructive Pulmonary Disease Treatment Market was valued at USD 89.95 billion in 2025 and is projected to grow to USD 96.64 billion in 2026, with a CAGR of 7.93%, reaching USD 153.50 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 89.95 billion
Estimated Year [2026] USD 96.64 billion
Forecast Year [2032] USD 153.50 billion
CAGR (%) 7.93%

A focused and contextual introduction that frames the clinical advances, device innovation, and commercial forces reshaping COPD treatment pathways worldwide

Chronic Obstructive Pulmonary Disease remains a leading cause of morbidity and healthcare utilization, and stakeholders across clinical, commercial, and policy domains must adapt to an accelerating pace of therapeutic and delivery innovation. Advances in long acting bronchodilators, targeted anti-inflammatory strategies, and inhalation device design are changing expectations for symptom control and exacerbation prevention. At the same time, shifts in reimbursement models and heightened attention to patient adherence and quality metrics are redefining value for payers and providers.

Consequently, clinicians are balancing established guideline-based therapy with growing interest in personalized treatment algorithms informed by biomarkers such as blood eosinophil counts. Device selection and inhalation technique have emerged as critical determinants of real-world effectiveness, prompting an emphasis on patient education and the integration of digital adherence tools. Pharmaceutical manufacturers and device companies are responding by prioritizing combination regimens, streamlined dosing formats, and improved user ergonomics that reduce misuse and enhance persistence.

Furthermore, the commercial landscape is shaped by evolving supply chains, regulatory scrutiny over manufacturing quality, and new entrants in generics and biosimilars that alter competitive dynamics. Taken together, these forces create both complexity and opportunity: stakeholders that align clinical evidence, device usability, and resilient supply strategies will be better positioned to deliver sustainable improvements in patient outcomes.

An incisive overview of the converging clinical, technological, and policy shifts that are redefining therapeutic strategies and commercial models in COPD care

The COPD treatment landscape is undergoing transformative shifts driven by converging clinical, technological, and policy developments. Clinically, the paradigm has moved beyond monotherapy toward combination regimens that integrate long acting bronchodilators with anti-inflammatory agents to target heterogeneous patient phenotypes. This clinical evolution is accompanied by the maturation of targeted pharmacologic classes and adjunctive approaches that address both symptom control and exacerbation risk.

Technologically, inhalation device innovation is accelerating. Dry powder inhalers, metered dose inhalers, and nebulizer platforms are receiving incremental redesigns to improve dose delivery and reduce user error, while digital adherence sensors and connected platforms are enabling new models of remote monitoring and patient engagement. These technologies are starting to influence prescribing behavior by providing objective adherence data that can be used in clinical decision making.

On the commercial and regulatory front, stakeholders face greater scrutiny of manufacturing quality and supply chain robustness, prompting strategies such as supplier diversification and regional manufacturing capacity expansion. Payer dynamics are shifting toward outcomes-oriented contracting and value demonstration, which favors therapies and delivery systems that show consistent real-world performance. Collectively, these shifts are redefining how therapies are developed, positioned, and delivered, and they create a competitive environment in which clinical differentiation and operational resilience are both essential for long term success.

A comprehensive analysis of how evolving import tariff measures are reshaping supply chains, procurement strategies, and clinical availability across COPD therapeutics

The introduction and escalation of tariff measures affecting pharmaceutical components, finished inhalation devices, and contract manufacturing inputs have created a material set of considerations for supply chain planners and commercial teams. Tariff-induced cost pressures tend to manifest through higher raw material and component prices, increased logistics and customs complexity, and reconfiguration of supplier relationships. In practice, manufacturers have been evaluating alternative sourcing geographies, negotiating longer term supplier contracts to lock in pricing, and accelerating onshore or nearshore capacity to mitigate exposure to tariff volatility.

Beyond procurement costs, tariffs can influence clinical availability through extended lead times and inventory management changes. Health systems and pharmacies may proactively increase stockholding of critical finished inhalers and parenteral therapies to buffer against supply interruptions, which in turn affects working capital and distribution planning. Regulatory agencies and trade bodies often respond with temporary waivers, expedited inspections, or tariff exemptions for essential medicines, but these mechanisms are not uniformly applied and can be slow to implement.

In addition, tariff dynamics tend to catalyze strategic behaviors such as consolidation of purchasing across hospital systems, expanded use of contract manufacturing organizations with diversified footprints, and increased investment in formulation or device adaptations that reduce reliance on import-sensitive components. For payers and providers, the cumulative effect is heightened attention to cost containment and continuity of care, while manufacturers must balance price pressure with continued investment in clinical differentiation and device innovation.

An integrative segmentation perspective highlighting how product types, drug classes, administration routes, and distribution channels jointly determine clinical use and commercial strategy in COPD care

Segmentation-driven insights illuminate how therapeutic demand, clinical utilization, and commercial channels interact across product types, drug classes, routes of administration, and distribution pathways. When considering product type, distinctions among antibiotics, corticosteroids, long acting bronchodilators, phosphodiesterase four inhibitors, and short acting bronchodilators reveal differentiated clinical roles: antibiotics are often episodic for infection management, corticosteroids serve as anti-inflammatory backbones in various delivery forms, long acting bronchodilators provide maintenance symptom control, phosphodiesterase four inhibitors target specific exacerbation-prone phenotypes, and short acting bronchodilators remain central to rescue therapy. These functional differences influence formulary placement, patient education priorities, and manufacturing cadence.

Examining drug class underscores the therapeutic mechanisms at play: anticholinergics and beta agonists are primary classes for bronchodilation, corticosteroids provide anti-inflammatory benefit in appropriate patients, and methylxanthines occupy a niche role where oral therapy is indicated. Route of administration further stratifies performance and adoption. Inhalation remains the preferred modality for targeted pulmonary delivery and is subdivided into dry powder inhalers, metered dose inhalers, and nebulizers, each with distinct patient suitability, device complexity, and adherence considerations. Intravenous formulations are primarily relevant in acute care settings, while oral agents offer systemic options for select patient groups.

Distribution channel analysis reveals differentiated access and service models. Hospital pharmacies support inpatient and acute care needs with tighter clinical oversight, online pharmacies present convenience and subscription models that can improve adherence but require robust authentication and cold chain considerations where applicable, and retail pharmacies provide broad community access and counseling touchpoints that are essential for long term therapy maintenance. Integrating these segmentation lenses enables targeted commercial strategies and clinical pathways that better match product characteristics to patient needs and operational realities.

A nuanced regional assessment describing how healthcare systems, regulatory frameworks, and supply chain capabilities shape COPD treatment approaches across global regions

Regional dynamics shape therapeutic priorities, regulatory pathways, and supply chain decisions in meaningful and distinctive ways. In the Americas, healthcare systems commonly emphasize value-based payment models and large integrated delivery networks that can support bundled care and adherence programs. This context encourages manufacturers to demonstrate real-world effectiveness and to partner with health systems on pilots that integrate digital adherence tools and patient education to reduce exacerbations and hospital readmissions.

In Europe, Middle East & Africa, the regulatory and reimbursement environment is heterogeneous, with well established national HTA frameworks in some markets and evolving access infrastructures in others. Stakeholders operating in this region must navigate country specific formularies and procurement mechanisms while also accounting for diverse device preferences and variable cold chain or distribution infrastructures in certain jurisdictions. Partnerships with local distributors and investments in regulatory expertise are common approaches to achieve consistent market entry and post launch support.

In the Asia-Pacific region, the landscape is marked by rapid uptake of generics, significant manufacturing capacity for APIs and finished dosage forms, and growing patient demand for accessible therapies. Policymakers and payers are increasingly focused on improving affordability while maintaining quality standards, which incentivizes contract manufacturing partnerships and regional supply hubs. Across all regions, digital health adoption, telemedicine, and remote monitoring are emerging enablers of improved COPD management, though the pace and nature of adoption vary by healthcare system maturity and reimbursement models.

A strategic examination of competitive positioning, partnership models, and innovation priorities that define company performance and collaboration in COPD therapeutics

Competitive dynamics among companies in the COPD space are driven by therapeutic differentiation, device innovation, strategic partnerships, and operational resilience. Innovator biopharmaceutical companies continue to focus on differentiated combination therapies and targeted anti-inflammatory approaches that can demonstrate clinical benefit across phenotypic subgroups. Device manufacturers are investing in human factors engineering and digital connectivity features to reduce misuse and to capture adherence data that support value arguments with payers and providers.

Generic and specialty pharmaceutical firms are enhancing their portfolios through lifecycle management and by leveraging contract manufacturing to scale production efficiently. Contract development and manufacturing organizations are expanding capacity in regions with favorable regulatory frameworks to support rapid commercial supply and to reduce geopolitical exposure. Meanwhile, diagnostics and digital health providers are creating complementary offerings-such as remote monitoring platforms and inhaler sensors-that enrich therapeutic value propositions and enable new care pathways focused on prevention of exacerbations.

Mergers, acquisitions, and strategic alliances are common tactics to accelerate time to market for novel formulations and device integrations. Across the competitive landscape, success increasingly hinges on the ability to align clinical evidence generation with pragmatic delivery solutions and to demonstrate consistent real-world outcomes that resonate with payers, providers, and patients.

Actionable recommendations for executives focusing on product differentiation, supply chain resilience, digital integration, and payer alignment to drive sustained competitive advantage in COPD care

Industry leaders can strengthen their competitive posture by pursuing a cohesive set of operational and clinical priorities that align with payer expectations and patient needs. First, integrating device design improvements with evidence generation plans ensures that new delivery formats are supported by outcomes data demonstrating reduced misuse and improved adherence. Complementing product innovation with robust post market surveillance and real-world evidence generation helps to validate value propositions and to inform label expansions and reimbursement negotiations.

Second, companies should prioritize supply chain resilience by diversifying supplier bases, qualifying dual sources for critical APIs and components, and evaluating regional manufacturing partnerships to reduce exposure to tariff and logistical volatility. Strategic inventory policies and collaborative forecasting with major purchasers can also reduce stockout risk while limiting excess inventory costs. Third, investing in digital health adjuncts-such as connected inhaler technologies and remote monitoring platforms-creates differentiation and supports clinical workflows that reduce acute utilization.

Finally, proactive payer engagement and outcome based contracting pilots can accelerate access while aligning incentives around reduced exacerbations and hospitalizations. By combining these levers-product and device innovation, supply chain diversification, digital integration, and value-based commercial models-industry leaders can achieve sustainable differentiation and better patient outcomes.

A rigorous, multi method research approach combining literature synthesis, expert interviews, real world utilization analysis, and supply chain mapping to inform actionable insights

The research underpinning this analysis used a multi method approach designed to triangulate clinical, commercial, and supply chain signals. A structured review of peer reviewed literature and regulatory guidance documents established the clinical context and informed classification of therapeutic and device modalities. This was augmented by qualitative interviews with clinical specialists, hospital pharmacy directors, device engineers, and supply chain managers to capture frontline perspectives on adherence challenges, device usability, and procurement pressures.

In addition, proprietary analysis of anonymized claims and utilization datasets provided insights into treatment patterns and care settings, while inspection of public regulatory filings and device approvals clarified recent innovation trajectories. Supply chain mapping exercises identified common points of vulnerability for APIs and device components, and scenario planning workshops informed the assessment of tariff impacts and mitigation strategies. Throughout, methodological rigor was maintained by cross checking primary data sources against independent clinical guidelines and regulatory outcomes to ensure consistency and to highlight areas of divergence that warrant further investigation.

A conclusive synthesis emphasizing the imperative to integrate clinical innovation, device usability, and supply chain resilience to advance COPD patient outcomes and commercial success

In conclusion, the COPD treatment ecosystem is at an inflection point where clinical innovation, device evolution, supply chain strategy, and payer expectations intersect to redefine value delivery. Stakeholders that integrate evidence based therapy selection with device usability improvements and digital adherence supports are positioned to achieve better patient outcomes. Concurrently, commercial success requires operational resilience-diversified sourcing, regional manufacturing options, and collaborative forecasting-to mitigate tariff and logistical risks that could disrupt availability and increase costs.

Going forward, alignment across the product lifecycle-from R&D through post market surveillance-and close collaboration with payers and providers will be essential. Decision makers should view the current environment as an opportunity to consolidate learnings from pilot programs, scale interventions that demonstrably reduce exacerbations, and invest in technologies that support sustained adherence. With thoughtful execution, organizations can translate emerging science and device capabilities into meaningful improvements in COPD care while safeguarding supply continuity and competitive positioning.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Chronic Obstructive Pulmonary Disease Treatment Market, by Product Type

  • 8.1. Antibiotics
  • 8.2. Corticosteroids
  • 8.3. Long Acting Bronchodilators
  • 8.4. Phosphodiesterase Four Inhibitors
  • 8.5. Short Acting Bronchodilators

9. Chronic Obstructive Pulmonary Disease Treatment Market, by Drug Class

  • 9.1. Anticholinergics
  • 9.2. Beta Agonists
  • 9.3. Corticosteroids
  • 9.4. Methylxanthines

10. Chronic Obstructive Pulmonary Disease Treatment Market, by Route Of Administration

  • 10.1. Inhalation
    • 10.1.1. Dry Powder Inhaler
    • 10.1.2. Metered Dose Inhaler
    • 10.1.3. Nebulizer
  • 10.2. Intravenous
  • 10.3. Oral

11. Chronic Obstructive Pulmonary Disease Treatment Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies

12. Chronic Obstructive Pulmonary Disease Treatment Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Chronic Obstructive Pulmonary Disease Treatment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Chronic Obstructive Pulmonary Disease Treatment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Chronic Obstructive Pulmonary Disease Treatment Market

16. China Chronic Obstructive Pulmonary Disease Treatment Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AstraZeneca PLC
  • 17.6. Aurobindo Pharma Ltd.
  • 17.7. Boehringer Ingelheim International GmbH
  • 17.8. Chiesi Farmaceutici S.p.A.
  • 17.9. Cipla Ltd.
  • 17.10. GlaxoSmithKline plc
  • 17.11. Glenmark Pharmaceuticals Ltd.
  • 17.12. Hikma Pharmaceuticals PLC
  • 17.13. Lupin Limited
  • 17.14. Merck & Co., Inc.
  • 17.15. Mylan N.V.
  • 17.16. Novartis AG
  • 17.17. Orion Corporation
  • 17.18. Pfizer Inc.
  • 17.19. Sun Pharmaceutical Industries Ltd.
  • 17.20. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY LONG ACTING BRONCHODILATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY LONG ACTING BRONCHODILATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY LONG ACTING BRONCHODILATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE FOUR INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE FOUR INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE FOUR INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY SHORT ACTING BRONCHODILATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY SHORT ACTING BRONCHODILATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY SHORT ACTING BRONCHODILATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY BETA AGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY BETA AGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY BETA AGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY METHYLXANTHINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY METHYLXANTHINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY METHYLXANTHINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRY POWDER INHALER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRY POWDER INHALER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRY POWDER INHALER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY METERED DOSE INHALER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY METERED DOSE INHALER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY METERED DOSE INHALER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY NEBULIZER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY NEBULIZER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY NEBULIZER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 68. NORTH AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. LATIN AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. LATIN AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. MIDDLE EAST CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. MIDDLE EAST CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 96. MIDDLE EAST CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 97. MIDDLE EAST CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 101. AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 103. AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 115. ASEAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 116. ASEAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. GCC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GCC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. GCC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 120. GCC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 121. GCC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 122. GCC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPEAN UNION CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPEAN UNION CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPEAN UNION CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPEAN UNION CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 129. BRICS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. BRICS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. BRICS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 133. BRICS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 134. BRICS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 135. G7 CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. G7 CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. G7 CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 138. G7 CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 139. G7 CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 140. G7 CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. NATO CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. NATO CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. NATO CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 144. NATO CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 145. NATO CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 146. NATO CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 149. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 151. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 152. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 153. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 154. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 155. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 157. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 158. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 159. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)